MedTrace Logo

A Study in Patients With Rheumatoid Arthritis

NCT00966875 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 448

Last updated 2016-05-26

Study results available
· View outcomes & findings →

Summary

The primary purpose of the study is to help answer the following research questions, and not to provide treatment for Rheumatoid Arthritis (RA):

* The safety of LY2439821 and any side effects that might be associated with it.
* Whether LY2439821 can help participants with active RA.
* How much LY2439821 should be given to participants.

Conditions

Interventions

BIOLOGICAL

LY2439821

Subcutaneous

DRUG

Placebo

Subcutaneous

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT-5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-03-31
Completion
2012-06-30

Countries

  • United States
  • Argentina
  • Chile
  • Germany
  • India
  • Peru
  • Poland
  • Romania
  • Russia
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00966875 on ClinicalTrials.gov